-
COVERAGE MATTERS: INSURANCE TYPE AND ACCESS TO A USUAL SOURCE OF CARE IN MEDICAL EXPENDITURE PANEL SURVEY (2018-2023)
Mar 18, 2026, 21:38 PM -
GENERATIVE AI SECURES SYNTHETIC DATASETS OF NSCLC TRIAL COHORTS FOR RWD ANALYSIS: A PRIVACY-PRESERVING CASE STUDY
Mar 18, 2026, 21:38 PM -
EARLY-LIFE PAIN EXPERIENCES AND DEPRESSION ONSET AMONG CHILDREN WITH SICKLE CELL DISEASE A LONGITUDINAL ANALYSIS USING TEXAS MEDICAID DATA
Mar 18, 2026, 21:38 PM -
REAL-WORLD EXPERIENCE AND BURDEN OF COGNITIVE IMPAIRMENT IN NARCOLEPSY AND IDIOPATHIC HYPERSOMNIA: SURVEY RESULTS FROM THE ASPIRE STUDY
Mar 18, 2026, 21:38 PM -
EVOLUTION OF USE OF RWE BY REGULATORS - CASE OF EMA
Mar 18, 2026, 21:38 PM -
INFLAMMATORY BIOMARKERS AND RHEUMATOID ARTHRITIS: EVIDENCE FROM A US POPULATION-BASED NHANES STUDY
Mar 18, 2026, 21:38 PM -
GOAL INVENTORIES IN STANDARDIZED IMPLEMENTATION OF PERSONALIZED OUTCOME ASSESSMENTS USING GOAL ATTAINMENT SCALING: A LANDSCAPE ANALYSIS
Mar 18, 2026, 21:38 PM -
A TOTAL COST OF CARE (TCOC) MODELING TOOL TO EVALUATE SECOND-LINE TREATMENT COSTS FOR PATIENTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER (ES-SCLC)
Mar 18, 2026, 21:38 PM -
PSYCHOMETRIC PROPERTIES OF THE MULTIPLE MYELOMA SYMPTOM AND IMPACT QUESTIONNAIRE (MYSIM-Q) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): ANALYSIS OF THE MAJESTEC-3 STUDY
Mar 18, 2026, 21:38 PM -
COMPARISON OF HEALTHCARE COSTS BETWEEN RECONSTRUCTION PROCEDURE AND DIRECT AMPUTATION OF LOWER EXTREMITIES AMONG PATIENTS WITH DIABETIC NEUROPATHIC ARTHROPATHY
Mar 18, 2026, 21:38 PM -
REAL-WORLD SYMPTOMS AND IMPACTS OF NARCOLEPSY AND IDIOPATHIC HYPERSOMNIA: QUALITATIVE RESULTS USING SOCIAL MEDIA LISTENING METHODS
Mar 18, 2026, 21:38 PM -
TRENDS IN PREVENTABLE HOSPITALIZATIONS BEFORE AND AFTER MEDICAID EXPANSION IN KENTUCKY
Mar 18, 2026, 21:38 PM -
COMPARATIVE ANALYSIS OF THE EPIDEMIOLOGICAL BURDEN OF STROKE IN EASTERN, CENTRAL AND WESTERN EUROPE BASED ON GLOBAL BURDEN OF DISEASE STUDY DATA
Mar 18, 2026, 21:38 PM -
BREAK EVEN ANALYSIS FOR CONTRACEPTION PRESCRIBING SERVICES IN COMMUNITY PHARMACIES
Mar 18, 2026, 21:38 PM -
A COST-CONSEQUENCE ANALYSIS OF NOGAPENDEKIN ALFA INBAKICEPT-PMLN (NAI) IN COMBINATION WITH BACILLUS CALMETTE-GUÉRIN (BCG) VERSUS TAR-200 FOR BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER WITH CARCINOMA IN SITU±PAPILLARY DISEASE (NMIBC CIS)
Mar 18, 2026, 21:38 PM -
DEVELOPMENT OF A PROFESSIONAL FRAMEWORK FOR MARKET ACCESS WITHIN THE PHARMACEUTICAL INDUSTRY: A MULTI-METHODS STUDY
Mar 18, 2026, 21:38 PM -
POPULATION EFFECTS OF PNEUMOCOCCAL CONJUGATE VACCINES ON INVASIVE PNEUMOCOCCAL DISEASE IN CANADA — A TARGETED LITERATURE REVIEW
Mar 18, 2026, 21:38 PM -
WHAT MATTERS MOST TO PATIENTS IN WARFARIN MODELS OF CARE: A QUALITATIVE STUDY
Mar 18, 2026, 21:38 PM -
MODELING APPROACHES FOR VACCINE INDIRECT EFFECTS IN ECONOMIC EVALUATIONS: A SCOPING REVIEW OF PUBLISHED REVIEWS AND METHODOLOGICAL GUIDANCE
Mar 18, 2026, 21:38 PM -
A SURVEY OF HEOR LEADERS IN PHARMA ABOUT THE STATE OF HEOR
Mar 18, 2026, 21:38 PM
